• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Qilian International Holding Group Ltd Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

    7/17/23 10:30:00 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $QLI alert in real time by email

    JIUQUAN, China, July 17, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd (NASDAQ:QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, received notification (the "Notification Letter") from The Nasdaq Stock Market LLC ("Nasdaq"), dated July 13, 2023, that the Company is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on The Nasdaq Global Market (the "Nasdaq Global Market"). The Notification Letter is only a notification of deficiency and not a notice of delisting.

    Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's ordinary shares for the 30 consecutive business days from May 30, 2023 to July 12, 2023, the Company no longer meets the minimum bid price requirement.

    The Notification Letter does not impact the Company's listing on the Nasdaq Global Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until January 9, 2024 (the "Compliance Period"), to regain compliance with Nasdaq Listing Rule 5450(a)(1). To regain compliance, the Company's ordinary shares must have a closing bid price of at least US$1.00 for a minimum for 10 consecutive business days, and shall not have a closing bid price of $0.10 or less for ten consecutive trading days during the Compliance Period. In the event the Company does not regain compliance by January 9, 2024, the Company may be eligible for additional time to regain compliance or may face delisting, as the case may be.

    The Company's business operations are not affected by the receipt of the Notification Letter. The Company intends to monitor the closing bid price of its ordinary shares and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse share split of its outstanding ordinary shares, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.

    About Qilian International Holding Group Ltd

    Qilian International Holding Group Ltd, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China. It focuses on the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers. The Company's products are sold in more than 20 provinces in China. For more information, visit the Company's website at http://ir.qlsyy.net.

    Forward-Looking Statements

    This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; products demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China; the COVID-19 outbreak and its impact on our operations and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

    For more information, please contact: [email protected].

    Cision View original content:https://www.prnewswire.com/news-releases/qilian-international-holding-group-ltd-receives-nasdaq-notification-regarding-minimum-bid-price-deficiency-301878569.html

    SOURCE Qilian International Holding Group Limited

    Get the next $QLI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QLI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QLI
    SEC Filings

    View All

    SEC Form 6-K filed by Qilian International Holding Group Ltd.

    6-K - Qilian International Holding Group Ltd (0001779578) (Filer)

    6/6/24 4:15:24 PM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Qilian International Holding Group Ltd.

    6-K - Qilian International Holding Group Ltd (0001779578) (Filer)

    6/4/24 9:25:25 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Qilian International Holding Group Ltd.

    EFFECT - Qilian International Holding Group Ltd (0001779578) (Filer)

    5/17/24 12:15:27 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Qilian International Holding Group Ltd. Announces Trading Ticker Symbol to "BGM"

    CHENGDU, China, Aug. 13, 2024 /PRNewswire/ -- Qilian International Holding Group Ltd. ("Qilian" or the "Company") (NASDAQ:QLI), a China-based pharmaceutical and chemical products manufacturer, announced today that effective on August 11, 2024, its Class A ordinary shares will begin trading on the Nasdaq Capital Market under the ticker symbol "BGM". The new ticker symbol will replace the Company's current ticker symbol "QLI." No action by the Company's shareholders is required with respect to the ticker symbol change. The Company's Class A ordinary shares will continue to be listed on the Nasdaq Capital Market and the CUSIP number remains unchanged. About Qilian International Holding Group L

    8/13/24 8:00:00 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qilian International Holding Group Ltd Regained Compliance with Nasdaq's Minimum Bid Price Rule

    CHENGDU, China, July 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ:QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, today announced that on July 10, 2024, NASDAQ notified the Company that it has determined that for the 10 consecutive business days, from June 21, 2024 to July 9, 2024, the closing bid price of the Company's Class A ordinary shares has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and NASDAQ has closed this matter. About Qilian International Holding Group Ltd Qilian International Holding Group Ltd, headquartered in Gansu, China, is

    7/12/24 8:30:00 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Qilian International Holding Group Limited Announces 1 for 5 Reverse Share Split

    CHENGDU, China, June 18, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ:QLI) ("Qilian" or the "Company"), a China-based pharmaceutical and chemical products manufacturer, announced today that an 1 for 5 reverse split of its authorized share capital, was approved by the Company's board of directors on May 29, 2023 and will become effective on June 21, 2024. In connection with the reverse share split, the Company's shareholders will receive one new Class A ordinary share or Class B ordinary share of the Company for every five Class A ordinary shares or every five Class B ordinary shares they hold, respectively. The Company's Class A ordinary shares are expected to begi

    6/18/24 8:30:00 AM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $QLI
    Financials

    Live finance-specific insights

    View All

    Qilian International Holding Group Ltd Declares Special Cash Dividends to Shareholders

    JIUQUAN, China, Feb. 16, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd ((the ", Company", NASDAQ:QLI), a China-based pharmaceutical and chemical products manufacturer, announced today that the Company has declared a special one-time cash dividend of $0.05 per ordinary share, payable in cash on or about March 6, 2023, to shareholders of record on February 28, 2023. "Despite the impacts of COVID-19 on us in our last fiscal year, the Company maintained decent operating results and healthy cash flow. We expect better financial results as China announced a rollback of its anti-COVID measures." said Mr. Zhanchang Xin, CEO of the Company. About Qilian International Holding Group Ltd Q

    2/16/23 4:30:00 PM ET
    $QLI
    Biotechnology: Pharmaceutical Preparations
    Health Care